^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Multiple Myeloma

    1d
    Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=56 --> 27 | Trial completion date: Jul 2026 --> Jan 2027 | Trial primary completion date: Jul 2026 --> Jan 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    leflunomide
    1d
    GMMG-DADA: Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, University of Cologne | Recruiting --> Active, not recruiting | N=160 --> 67 | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Dec 2029 --> Mar 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1d
    NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Elvira Umyarova | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    SLAMF7 (SLAM Family Member 7)
    |
    cyclophosphamide • Sarclisa (isatuximab-irfc) • Hemady (dexamethasone tablets) • UD TGFbetai NK cells
    1d
    KarMMa-9: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P3, N=79, Active, not recruiting, Celgene | N=618 --> 79 | Trial completion date: Aug 2025 --> Nov 2029
    Enrollment change • Trial completion date
    |
    lenalidomide • cyclophosphamide • fludarabine IV • Abecma (idecabtagene vicleucel)
    1d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Completed --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    1d
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    clonoSEQ
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    1d
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca | N=64 --> 40
    Enrollment change
    |
    AZD0120
    2d
    EAY131-A: Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR L861Q • EGFR S768I
    |
    Gilotrif (afatinib)
    2d
    MRD2STOP: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients (clinicaltrials.gov)
    P=N/A, N=56, Active, not recruiting, University of Chicago | Trial completion date: Feb 2026 --> Apr 2028 | Trial primary completion date: Feb 2026 --> Apr 2028
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ
    2d
    EAY131-U: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    NF2 (Neurofibromin 2)
    |
    Fakzynja (defactinib)
    2d
    ALPS: One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Fondazione IRCCS Policlinico San Matteo di Pavia
    New trial
    2d
    Histone deacetylases: Function in tumor development and therapeutic prospects (Review). (PubMed, Oncol Lett)
    Furthermore, the present review discussed recent progress in structural modifications aimed at enhancing selectivity while reducing toxicity, as well as novel targeting strategies. Concluding with perspectives on HDAC-based therapies, the present review underscores the key importance of precision targeting and combinatorial approaches to improve patient outcomes in the future.
    Review • Journal
    |
    HDAC11 (Histone Deacetylase 11) • HDAC5 (Histone Deacetylase 5) • HDAC3 (Histone Deacetylase 3) • HDAC7 (Histone Deacetylase 7)